Herpes simplex viruses 1 and 2

Dermatologic Clinics

Volumn 20, Issue 2, 2002, Pages 249-266

  Yeung Yue, Kimberly A ^a,b   Brentjens, Mathijs H ^a   Lee, Patricia C ^a   Tyring, Stephen K ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; DNA VACCINE; FAMCICLOVIR; FLUOCINONIDE; FOSCARNET; IMIQUIMOD; PENCICLOVIR; RECOMBINANT VACCINE; RESIQUIMOD; VALACICLOVIR;

CLINICAL TRIAL; DIAGNOSTIC TEST; DISEASE SEVERITY; GEL; GENITAL HERPES; HERPES LABIALIS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INCIDENCE; KIDNEY DISEASE; NEPHROTOXICITY; NEUTROPENIA; PATHOGENESIS; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SEROLOGY; SKIN INFECTION; VIRUS CULTURE; VIRUS INFECTION; VIRUS TRANSMISSION; HERPES SIMPLEX;

HERPES GENITALIS; HERPES LABIALIS; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMAN; HUMANS;

EID: 0035986476     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(01)00003-1     Document Type: Review

References (162)

1. Herpes simplex viruses
2. Cold sores: A new understanding of their pathophysiology and the need for a new treatment
3. Seroepidemiological and sociological patterns of herpes simplex virus infection in the world
4. Herpes simplex virus type 2 in the United States, 1976 to 1994
5. Risk factors for the sexual transmission of genital herpes
6. Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: A prospective couple study
7. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women
8. Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase
9. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons
10. Recurrence rates in genital herpes after symptomatic first-episode infection
11. Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" herpes simplex virus type 2 infection
12. Virologic characteristics of subclinical and symptomatic genital herpes infections
13. Herpes simplex virus type 2 shedding in human immunodeficiency virus-negative men who have sex with men: Frequency, patterns, and risk factors
14. The current trend in genital herpes
15. A prospective study of new infections with HSV-1 and HSV-2
16. The association between genital ulcer disease and acquisition of HIV infection in homosexual men
17. Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals
18. High cumulative incidence of genital herpes amongst HIV-1 seropositive heterosexuals in south London
19. Prior herpes simplex virus type 2 infection as a risk factor for HIV infection
20. Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus 1
21. Direct recovery of herpes simplex virus (HSV)-specific T lymphocyte clones from recurrent genital HSV-2 lesions
22. Epidemiological synergy: Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases
23. Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women
24. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men
25. Cervical shedding of herpes simplex virus in human immunodeficiency virus-infected women: Effects of hormonal contraception, pregnancy, and vitamin A deficiency
26. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons: A double-blind, placebo-controlled trial
27. Frequent recovery of H1V-1 from genital herpes simplex virus lesions in HIV-1 infected men
28. The impact of active herpes simplex virus infection on human immunodeficiency virus load
29. Herpes simplex viral shedding and plasma human immunodeficiency virus RNA levels in coinfected women
30. Infections with herpes simplex viruses [first of two parts]
31. Management of neonatal herpes simplex virus infection
32. Viral disease update
33. Are reported stress and coping style associated with frequent recurrence of genital herpes?
34. Persistent stress as a predictor of genital herpes recurrence
35. Prophylactic chemotherapy with acyclovir for recurrent herpes simplex labialis
36. Demonstration of exogenous genital reinfection with herpes simplex virus type-2 by restriction endonuclease fingerprinting of viral DNA
37. Reinfection is an uncommon occurrence in patients with symptomatic recurrent genital herpes
38. Experimental human reinfection with herpes simplex virus
39. Reactions of autoinoculation for recurrent herpes simplex
40. Infection of the newborn with herpes virus hominis
41. Management of herpesvirus infections
42. The heterogeneous clinical spectrum of genital herpes
43. Herpes simplex: Evolving concepts
44. Recurrences after oral and genital herpes simplex virus infection: Influence of site of infection and viral type
45. Oral acyclovir to suppress frequently recurrent herpes labialis: A double-blind, placebo-controlled trial
46. Herpes simplex viruses
47. Newer aspects of herpesvirus infections
48. Genital herpes simplex virus infections: Clinical manifestations, course and complications
49. The diagnosis and treatment of genital herpes
50. Genital herpetic infection in men and women: Clinical course and effect of topical application of adenine arabinoside
51. Herpes simplex virus type 1 as a cause of genital herpes: Impact on surveillance and prevention
52. Herpes: Atypical clinical manifestations
53. Risk of recurrence after first episodes of genital herpes: Relation to HSV type and antibody response
54. Frequent genital herpes simplex virus 2 shedding in immunocompetent women
55. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir
56. Urinary retention probably secondary to herpes genitalis
57. Recurrent conjugal neuralgia caused by herpesvirus hominis type 2
58. Aseptic meningitis in association with herpes progenitalis
59. Genital herpes complicating pregnancy
60. Intrauterine herpes simplex virus infection
61. Herpetic whitlow: Epidemiology, clinical characteristics, diagnosis, and treatment
62. Herpetic whitlow: An occupational hazard
63. Kaposi's varicelliform eruption: Absence of ocular involvement
64. Viral folliculitis
65. Common ocular infections
66. Virus infections of the eye
67. Acyclovir for recurrent erythema multiforme caused by herpes simplex
68. Detection of herpes simplex virus DNA in cutaneous lesions of erythema multiforme
69. Herpes simplex in childhood erythema multiforme
70. Relation between herpes simplex viruses and human immunodeficiency virus infections
71. Acyclovir prevents reactivation of herpes simplex labialis in skiers
72. Tests for detecting herpes simplex virus and varicella-zoster virus infections
73. Current diagnostic techniques in genital herpes: Their role in controlling the epidemic
74. Sorting out the new HSV type specific antibody tests
75. Evaluation of a novel point of care test for antibodies to herpes simplex virus type 2
76. Premarket evaluation of the POCkit HSV-2 type-specific serologic test in culture-documented cases of genital herpes simplex virus type 2
77. An evaluation of near patient tests for detecting herpes simplex virus type-2 antibody
78. Clinical course of patients with serologic evidence of recurrent genital herpes presenting with signs and symptoms of first episode disease
79. Thymidine kinase from herpes simplex virus phosphorylates: The new antiviral compound, 9 (2 hydroxyethoxymethyl)guanine
80. Inhibition of purified human and herpes simplex virus-induced DNA polymerase by 9-(2-hydroxyethoxymethyl)guanine [acyclovir] triphosphate: Effect on primer-template function
81. Peroral famciclovir in the treatment of experimental ultraviolet radiation-induced herpes simplex labialis: A double-blind, dose-ranging, placebo-controlled, multicenter trial
82. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection: Results of an international, multicenter, double-blind, randomized clinical trial
83. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections
84. Valacyclovir for the suppression of recurrent genital herpes simplex virus infection: A large-scale dose range-finding study
85. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans
86. Drugs five years later: Acyclovir
87. Acyclovir: Mechanism of action, pharmacokinetics, safety and clinical applications
88. Oral famciclovir for the suppression of recurrent genital herpes: A randomized controlled trial
89. Herpes simplex
90. Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infections
91. Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection
92. Renal function after acyclovir intravenous injection
93. Acyclovir induced renal failure: Course and risk factors
94. Acute renal failure and coma secondary to acyclovir therapy
95. Therapy of herpes zoster with oral acyclovir
96. Severe but reversible neurotoxicity from acyclovir
97. Neurologic symptoms associated with parenteral acyclovir treatment after bone marrow transplantation
98. Penciclovir cream for the treatment of sunlight-induced herpes simplex labialis: A randomized, double-blind, placebo-controlled trial
99. Penciclovir cream for the treatment of herpes simplex labialis: A randomized, multicenter, double-blind, placebo-controlled trial
100. Treatment of herpes simplex gingivostomatitis with aciclovir in children: A randomised double blind placebo controlled study
101. Oral acyclovir and herpes labialis: A randomized, double-blind, placebo-controlled study
102. Treatment of recurrent herpes simplex labialis with oral acyclovir
103. Combination treatment with famciclovir and a topical corticosteroid gel versus famciclovir alone for experimental ultraviolet radiation-induced herpes simplex labialis: A pilot study
104. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir
105. Double-blind placebo-controlled trial of oral acyclovir in firstepisode genital herpes simplex virus infection
106. Double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection
107. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes
108. Acyclovir: Pharmacology and clinical experience
109. Pharmacokinetics in acyclovir in humans following intravenous administration: A model for the development of parenteral antivirals
110. Intravenous acyclovir for treatment of primary genital herpes
111. Intravenous acyclovir therapy of first episodes of genital herpes: A multicenter double-blind, placebo-controlled trial
112. Famciclovir in the management of first-episode genital herpes
113. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis
114. A comparison of oral valaciclovir 500 mg twice daily for three or five days in the treatment of recurrent genital herpes
115. Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: A parallel-groups, randomized, double-blind clinical trial
116. Effect of oral acyclovir treatment on symptomatic and asymptomatic shedding in recurrent genital herpes
117. Acyclovir suppression of frequently recurring genital herpes: Efficacy and diminishing need during successive years of treatment
118. Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: A pilot study
119. Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848
120. Acyclovir in pregnancy registry: An observational epidemiological approach
121. Pregnancy outcomes following systemic prenatal acyclovir exposure: June 1, 1984-June 30, 1993
122. Herpesviruses in the immunocompromised host
123. Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host
124. Sequential intravenous and twice-daily oral acyclovir for extended prophylaxis of herpes simplex virus infection in marrow transplant patients
125. Efficacy and safety of famciclovir for the treatment of HSV infection in HIV+ patients [oral presentation 301]
126. Intravenous penciclovir for treatment of herpes simplex infections in immunocompromised patients: Results of a multicenter, acyclovir-controlled trial
127. Recurrent genital herpes and suppressive oral acyclovir therapy
128. Survey of resistance of herpes simplex virus to acyclovir in northwest England
129. Brief report: Recurrent acyclovir-resistant genital herpes in an immunocompetent patient
130. Management of acyclovir-resistant herpes simplex and varicellazoster virus infections
131. Recurrence and resistance patterns of herpes simplex virus following cessation of > 6 years of chronic suppression with acyclovir
132. Herpes simplex resistance to acyclovir: A study in a tertiary care centre
133. Isolation and characterisation of resistant herpes simplex virus after acyclovir therapy
134. Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir
135. Herpes simplex virus resistance to acyclovir: Clinical relevance
136. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome
137. Disseminated acyclovir-resistant herpes simplex virus type 2 treated successfully with foscamet
138. Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation
139. Herpes simplex virus type 2 meningoencephalitis resistant to acyclovir in a patient with AIDS
140. Progressive esophagitis from acyclovir-resistant herpes simplex: Clinical roles for DNA polymerase mutants and viral heterogeneity
141. Mucocutaneous dissemination of acyclovir-resistant herpes simplex virus in a patient with AIDS
142. Varicella pneumonia in adults: Report of seven cases and review of the literature
143. Successful foscamet therapy for acyclovir-resistant mucocutaneous infection with herpes simplex virus in a recipient of allogeneic BMT
144. Mechanism of action of foscamet against viral polymerases
145. Antiviral effects of phosphonoformate (PFA, foscamet sodium)
146. Review of the toxicities of foscamet
147. Foscametresistant herpes simplex virus infection in patients with AIDS
148. Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infection
149. Heterogeneity of a herpes simplex virus clinical isolate exhibiting resistance to acyclovir and foscamet
150. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscamet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC)
151. Treatment of acyclovir-resistant, foscamet-unresponsive HSV infection with topical cidofovir in a child with AIDS
152. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS
153. Antiviral therapy of herpes simplex
154. Cidofovir use in acyclovir-resistant herpes infection
155. Herpesvirus vaccines: Development, controversies, and applications
156. Prospects for control of herpes simplex virus disease through immunization
157. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease
158. Induction of a protective immune repsonse by mucosal vaccination with a DISC HSV-1 vaccine
159. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: Two randomized controlled trials
160. Virology for the dermatologist
161. Safety, humoral and cellular immune responses of three different doses of glycoprotein d (gD2t) in herpes simplex vaccine with aluminum and MPL
162. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes: A randomized, double-blind multicenter trial